Drug Approval | May 29, 2025
Zydus receives USFDA ‘Fast Track Designation’ for novel oral inhibitor ‘Usnoflast’
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Usnoflast has previously also received ‘Orphan Drug Designation (ODD)’ from the USFDA
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
The overall clinical efficacy of Zaynich across indications was 98% at the test-of-cure
Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country
ALS patients experience neuroinflammation and rapid neurodegeneration
The patient has been isolated in a designated hospital and is currently stable
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Monkeypox infections are usually self-limiting lasting between 2-4 weeks and patients generally recover with supportive management
Subscribe To Our Newsletter & Stay Updated
